Pharmacokinetics of enoximone after various intravenous administrations to healthy volunteers. 1995

S Morita, and Y Sawai, and J F Heeg, and Y Koike
Marion Merrell Dow Development Laboratories, Hirakata Center, Osaka, Japan.

The pharmacokinetics of enoximone and its sulfoxide metabolite were investigated in healthy male volunteers after various intravenous administrations: a bolus single dose, a continuous infusion, and bolus multiple doses of enoximone. The overall pharmacokinetic profiles of enoximone and sulfoxide metabolite indicated linearity over the range of 0.25-2.0 mg/kg after single doses of enoximone. The hypothetical plasma concentration just after bolus injection of enoximone, the maximum concentration of sulfoxide, and the area under the concentration-time curves of both compounds increased proportionally with dose. The terminal half-lives of both compounds indicated similar values (2.0-2.7 h) and were not dose related. After four consecutive doses given at 3-h intervals, no accumulation was observed for either compound, and the pharmacokinetic parameters were not altered. After a 4-h infusion of enoximone, the areas under the plasma concentration-time curves of both compounds were 30% lower than the estimated values from the single dose study. Also, some pharmacokinetic parameters were changed as compared to those from the single dose study. The pharmacokinetic parameters obtained in Japanese healthy volunteers showed no marked differences from those obtained in Caucasians; thus, no racial difference was suggested in the pharmacokinetic properties of enoximone.

UI MeSH Term Description Entries
D007262 Infusions, Intravenous The long-term (minutes to hours) administration of a fluid into the vein through venipuncture, either by letting the fluid flow by gravity or by pumping it. Drip Infusions,Intravenous Drip,Intravenous Infusions,Drip Infusion,Drip, Intravenous,Infusion, Drip,Infusion, Intravenous,Infusions, Drip,Intravenous Infusion
D007275 Injections, Intravenous Injections made into a vein for therapeutic or experimental purposes. Intravenous Injections,Injection, Intravenous,Intravenous Injection
D008297 Male Males
D008954 Models, Biological Theoretical representations that simulate the behavior or activity of biological processes or diseases. For disease models in living animals, DISEASE MODELS, ANIMAL is available. Biological models include the use of mathematical equations, computers, and other electronic equipment. Biological Model,Biological Models,Model, Biological,Models, Biologic,Biologic Model,Biologic Models,Model, Biologic
D002851 Chromatography, High Pressure Liquid Liquid chromatographic techniques which feature high inlet pressures, high sensitivity, and high speed. Chromatography, High Performance Liquid,Chromatography, High Speed Liquid,Chromatography, Liquid, High Pressure,HPLC,High Performance Liquid Chromatography,High-Performance Liquid Chromatography,UPLC,Ultra Performance Liquid Chromatography,Chromatography, High-Performance Liquid,High-Performance Liquid Chromatographies,Liquid Chromatography, High-Performance
D006207 Half-Life The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity. Halflife,Half Life,Half-Lifes,Halflifes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D013454 Sulfoxides Organic compounds that have the general formula R-SO-R. They are obtained by oxidation of mercaptans (analogous to the ketones). (From Hackh's Chemical Dictionary, 4th ed)
D017335 Enoximone A selective phosphodiesterase inhibitor with vasodilating and positive inotropic activity that does not cause changes in myocardial oxygen consumption. It is used in patients with CONGESTIVE HEART FAILURE. Fenoximone,MDL 19438,MDL-17,043,MDL-17043,MDL-19,438,Perfan,MDL 17,043,MDL 17043,MDL 19,438,MDL17,043,MDL17043,MDL19,438

Related Publications

S Morita, and Y Sawai, and J F Heeg, and Y Koike
November 2011, International journal of clinical pharmacology and therapeutics,
S Morita, and Y Sawai, and J F Heeg, and Y Koike
October 2007, Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan,
S Morita, and Y Sawai, and J F Heeg, and Y Koike
August 2015, Antimicrobial agents and chemotherapy,
S Morita, and Y Sawai, and J F Heeg, and Y Koike
December 1990, Arzneimittel-Forschung,
S Morita, and Y Sawai, and J F Heeg, and Y Koike
January 1989, Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin. Erganzungsband,
S Morita, and Y Sawai, and J F Heeg, and Y Koike
October 2014, Acta pharmaceutica Sinica. B,
S Morita, and Y Sawai, and J F Heeg, and Y Koike
March 1992, Antimicrobial agents and chemotherapy,
S Morita, and Y Sawai, and J F Heeg, and Y Koike
April 1994, Journal of pharmacokinetics and biopharmaceutics,
S Morita, and Y Sawai, and J F Heeg, and Y Koike
January 1984, Physiological chemistry and physics and medical NMR,
Copied contents to your clipboard!